skip to main content

H.R. 3348 (115th): Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome.

The bill’s titles are written by its sponsor.

Sponsor and status

Scott Peters

Sponsor. Representative for California's 52nd congressional district. Democrat.

Read Text »
Last Updated: Jul 20, 2017
Length: 2 pages
Introduced:

Jul 20, 2017
115th Congress, 2017–2019

Status:
Died in a previous Congress

This bill was introduced on July 20, 2017, in a previous session of Congress, but was not enacted.

History

Jul 20, 2017
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

H.R. 3348 (115th) was a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

This bill was introduced in the 115th Congress, which met from Jan 3, 2017 to Jan 3, 2019. Legislation not enacted by the end of a Congress is cleared from the books.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 3348 — 115th Congress: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act.” www.GovTrack.us. 2017. February 19, 2019 <https://www.govtrack.us/congress/bills/115/hr3348>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.